These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34477531)

  • 1. Breaking the Silence of Tumor Response: Future Prospects of Targeted Radionuclide Therapy.
    Pareri AU; Koijam AS; Kumar C
    Anticancer Agents Med Chem; 2022; 22(10):1845-1858. PubMed ID: 34477531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted alpha therapy: part I.
    Elgqvist J
    Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radionuclide cancer therapy.
    Hoefnagel CA
    Ann Nucl Med; 1998 Apr; 12(2):61-70. PubMed ID: 9637275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?
    Guerard F; Barbet J; Chatal JF; Kraeber-Bodere F; Cherel M; Haddad F
    Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):161-7. PubMed ID: 25752501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted radionuclide therapy--an overview.
    Dash A; Knapp FF; Pillai MR
    Curr Radiopharm; 2013 Sep; 6(3):152-80. PubMed ID: 24059327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
    Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
    Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mathematical Model for Evaluation of Tumor Response in Targeted Radionuclide Therapy with
    Yonekura Y; Toki H; Watabe T; Kaneda-Nakashima K; Shirakami Y; Ooe K; Toyoshima A; Nakajima H; Tomiyama N; Bando M
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
    de Visser M; Verwijnen SM; de Jong M
    Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches for imaging and therapy of solid cancer.
    Sollini M; Boni R; Traino AC; Lazzeri E; Pasqualetti F; Modeo L; Mariani G; Petrini M; Erba PA
    Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):168-83. PubMed ID: 25693421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide receptor radionuclide therapy: an overview.
    Dash A; Chakraborty S; Pillai MR; Knapp FF
    Cancer Biother Radiopharm; 2015 Mar; 30(2):47-71. PubMed ID: 25710506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in nuclear oncology: microspheres for internal radionuclide therapy of liver tumours.
    Nijsen JF; van het Schip AD; Hennink WE; Rook DW; van Rijk PP; de Klerk JM
    Curr Med Chem; 2002 Jan; 9(1):73-82. PubMed ID: 11860349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of radiobiological concepts in radionuclide therapy of cancer.
    Kumar C; Shetake N; Desai S; Kumar A; Samuel G; Pandey BN
    Int J Radiat Biol; 2016; 92(4):173-86. PubMed ID: 26917443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.
    Thiele NA; Wilson JJ
    Cancer Biother Radiopharm; 2018 Oct; 33(8):336-348. PubMed ID: 29889562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.
    Uusijärvi H; Bernhardt P; Ericsson T; Forssell-Aronsson E
    Med Phys; 2006 Sep; 33(9):3260-9. PubMed ID: 17022220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination radionuclide therapy: A new paradigm.
    Suman SK; Subramanian S; Mukherjee A
    Nucl Med Biol; 2021; 98-99():40-58. PubMed ID: 34029984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic radionuclides in nuclear medicine: current and future prospects.
    Yeong CH; Cheng MH; Ng KH
    J Zhejiang Univ Sci B; 2014 Oct; 15(10):845-63. PubMed ID: 25294374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
    Lee D; Li M; Bednarz B; Schultz MK
    Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radionuclides in radiation-induced bystander effect; may it share in radionuclide therapy?
    Widel M
    Neoplasma; 2017; 64(5):641-654. PubMed ID: 28592116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis.
    Zhu X; Palmer MR; Makrigiorgos GM; Kassis AI
    Med Phys; 2010 Jun; 37(6):2974-84. PubMed ID: 20632610
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Li M; Sagastume EA; Lee D; McAlister D; DeGraffenreid AJ; Olewine KR; Graves S; Copping R; Mirzadeh S; Zimmerman BE; Larsen RH; Johnson FL; Schultz MK
    Curr Med Chem; 2020; 27(41):7003-7031. PubMed ID: 32720598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.